Hefei Hengxin Life Science and Technology
301501
Triductor Technology
688259
Zhejiang Sf Oilless Bearing Co.,Ltd.
300817
Shenzhen Riland Industry Group
300154
Chengdu TangYuan Electric
300789
CN Stock MarketDetailed Quotes
600056 China Meheco Group
- 10.77
- -0.02-0.19%
Not Open Mar 19 15:00 CST
16.11BMarket Cap17.89P/E (TTM)
10.83High10.74Low87.94KlotVolume10.77Open10.79Pre Close94.83MTurnover0.59%Turnover Ratio15.36P/E (Static)1.50BShares13.8852wk High1.38P/B16.10BFloat Cap9.4552wk Low11.87Limit Up1.50BShs Float31.11Historical High9.71Limit Down0.83%Amplitude-1.82Historical Low0.23Dividend TTM10.78Avg Price43.72KlotAsk2.15%Div YieldTTM100Lot Size43.22KlotBid
China Meheco Group News
Meheco Unit's Tranexamic Acid Injection Passes Regulatory Evaluation
China Meheco Group (600056.SH): Tranexamic Acid Injection has passed the consistency evaluation for generic drugs.
On March 10, Gelonghui reported that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. had received an approval notice from the National Medical Products Administration for a supplementary application for tranexamic acid injection, which has passed the consistency evaluation of the quality and efficacy of generic drugs. Tranexamic acid injection is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis, which was originally developed by Daiichi Sankyo Company, Limited in Japan and was approved for market in Japan in 1965.
Meheco's Unit Gets Nod to Market Sacubitril-Valsartan Sodium Tablets
The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.
① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.
[Brokerage Focus] CMB International indicates that China Meheco Group has started a valuation recovery.
Jinwu Financial News | China Merchants International states that the MSCI Chinese Medical Index has risen 5.3% year-to-date as of early 2025, outperforming the MSCI Chinese Index by 0.9%. Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a highly elastic industry, is expected to outperform the market in 2025. The Category C medical insurance directory is set to be implemented within the year, and Innovative Drugs will benefit from better payment conditions through commercial health insurance coverage. The bidding for Medical Devices is accelerating its recovery, which will drive the profit recovery of domestic medical device companies. The bank is Bullish about the recovery of industry valuations. It recommends buying WUXI APPTEC (02359, 603259 CH).
Zhaoyin International: Bullish on the valuation repair of the China Meheco Group Industry, recommending to Buy WUXI APPTEC (02359) and others.
Cinda International believes that China will become a necessary place for overseas pharmaceutical companies to seek innovative drug pipelines, and innovative drugs from China will play an increasingly important role on the international stage.
China Meheco Group (SHSE:600056) Shareholders Notch a 14% CAGR Over 3 Years, yet Earnings Have Been Shrinking
Announcement on the pre-reduction of 2024 results
China Meheco Group (600056.SH): The net income for the year 2024 is expected to decrease by 68% to 45%.
Glory Network reported on January 24 that China Meheco Group (600056.SH) announced a reduction in the 2024 annual performance forecast. According to preliminary calculations by the financial department, it is expected that the net income attributable to shareholders of the listed company will be between 0.335 billion yuan and 0.576 billion yuan, representing a year-on-year decrease of 68% to 45%. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be between 0.231 billion yuan and 0.472 billion yuan, which is a year-on-year decrease of 62% to 23%. This reduction in performance is primarily due to the impacts of domestic centralized procurement price reductions, increased market competition, and tightening international demand.
Meheco Unit's Flumazenil Injection Passes Consistency Evaluation
CMB International: With continued policy efforts, Bullish on the rebound of China Meheco Group's valuation.
Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a high-elasticity Industry, is expected to outperform the market in 2025.
China Meheco Group Co., Ltd.'s (SHSE:600056) Share Price Is Matching Sentiment Around Its Earnings
Meheco Unit's Angina Tablets Passes Chinese Drug Regulator's Consistency Evaluation
Meheco Unit's Sepsis Drug Included in China's Centralized Procurement Bid
China Meheco Group (600056.SH): Sodium piperacillin for injection is expected to be selected for centralized procurement.
China Meheco Group (600056.SH) announced that on December 12, 2024, its subsidiary in Hainan...
Meheco Receives Nod for Influenza Drug's Registration
China Meheco Group (600056.SH): Subsidiary obtained pharmaceutical registration approval.
On December 4th, Gelonghui reported that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceuticals Co., Ltd. (referred to as "Tianfang Pharmaceuticals"), received an approved pharmaceutical registration certificate from the National Medical Products Administration for a phosphor oseltamivir capsule (referred to as "the pharmaceutical"). Phosphor oseltamivir is a precursor drug of its active metabolite (oseltamivir carboxylate), which is a selective neuraminidase inhibitor for influenza viruses.
Xinkangjie: From January to August 2024, the sales scale of pharmaceuticals in the china meheco group retail market reached 324.4 billion yuan, with a year-on-year growth of 1.4%.
In terms of distribution channels, the scale of retail pharmacies (including O2O) accounts for 87.0%, with a year-on-year growth rate of 0.3%; the scale of e-commerce B2C accounts for 13.0%, with a year-on-year growth rate of 9.6%, and the scale proportion has increased by 1.0% year-on-year, highlighting the importance of the channel.
Meheco Gets Supplementary Drug Approval for ADHD Drug
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.
